Literature DB >> 1931822

Trans-dominant Tat mutants with alterations in the basic domain inhibit HIV-1 gene expression.

N Modesti1, J Garcia, C Debouck, M Peterlin, R Gaynor.   

Abstract

The Tat protein of the human immunodeficiency virus type 1 (HIV-1) is required for efficient viral gene expression. By means of mutational analyses, several domains of the Tat protein that are required for complete activation of HIV-1 gene expression have been defined. These include an amino-terminal activating domain, a cysteine-rich dimerization domain, and a basic domain important in the binding of Tat to the trans-activation response element (TAR) and in Tat nuclear localization. Recently, we described a mutation, known as delta tat, which resulted in a protein with a truncated basic domain. This protein had a "trans-dominant" phenotype in that it inhibited wild-type Tat activation of the HIV-1 LTR. To further characterize the requirements for generating a Tat trans-dominant phenotype, we constructed a variety of Tat proteins with truncations or substitutions in the basic domain. A number of these proteins showed a trans-dominant phenotype. These Tat mutants also inhibited activation of the HIV-1 LTR by a protein composed of Tat fused to the prokaryotic R17 (phage MS2) RNA-binding protein in which the R17 recognition element was inserted in the HIV-1 LTR in place of TAR. Thus, an intact TAR element was not required for this inhibition. We also studied the cellular localization of Tat and a trans-dominant Tat mutant by means of immunofluorescence staining with the use of antibodies reactive to different domains of the Tat protein. The results indicated that Tat becomes localized predominantly in the nucleus both in the presence and absence of the trans-dominant Tat construct, suggesting that the trans-dominant mutant does not inhibit Tat nuclear localization. These studies further define the requirements for the creation of trans-dominant Tat mutants, and suggest that the mechanism of trans-dominant Tat inhibition may be either the formation of an inactive complex between wild-type and mutant Tat or sequestration of cellular factors involved in regulating HIV-1 gene expression.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1931822

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  27 in total

1.  gag, vif, and nef genes contribute to the homologous viral interference induced by a nonproducer human immunodeficiency virus type 1 (HIV-1) variant: identification of novel HIV-1-inhibiting viral protein mutants.

Authors:  P D'Aloja; E Olivetta; R Bona; F Nappi; D Pedacchia; K Pugliese; G Ferrari; P Verani; M Federico
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 2.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

3.  Inhibition of human immunodeficiency virus type 1 and type 2 Tat function by transdominant Tat protein localized to both the nucleus and cytoplasm.

Authors:  M J Orsini; C M Debouck
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.

Authors:  Min-Hsuan Lin; Ann Apolloni; Vincent Cutillas; Haran Sivakumaran; Sally Martin; Dongsheng Li; Ting Wei; Rui Wang; Hongping Jin; Kirsten Spann; David Harrich
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

5.  Transition step during assembly of HIV Tat:P-TEFb transcription complexes and transfer to TAR RNA.

Authors:  Iván D'Orso; Gwendolyn M Jang; Alexander W Pastuszak; Tyler B Faust; Elizabeth Quezada; David S Booth; Alan D Frankel
Journal:  Mol Cell Biol       Date:  2012-09-24       Impact factor: 4.272

6.  A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.

Authors:  Ann Apolloni; Min-Husan Lin; Haran Sivakumaran; Dongsheng Li; Michael H R Kershaw; David Harrich
Journal:  Hum Gene Ther       Date:  2013-03-01       Impact factor: 5.695

7.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope deletion mutant.

Authors:  K R Steffy; F Wong-Staal
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

9.  Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator.

Authors:  D Bevec; M Dobrovnik; J Hauber; E Böhnlein
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Potent inhibition of HIV-1 replication by a Tat mutant.

Authors:  Luke W Meredith; Haran Sivakumaran; Lee Major; Andreas Suhrbier; David Harrich
Journal:  PLoS One       Date:  2009-11-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.